Related Experiment Video
Updated: Oct 16, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Don't Compromise Myeloma Care Due to COVID-19 Pandemic!
Nikhil C Munshi1,2, Kenneth C Anderson1
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Abstract:
Patients with active myeloma, especially with earlier stages of the disease, are susceptible to COVID-19 infection and can have adverse outcomes, even in those on first-line treatment. Importantly, myeloma therapy can be safely administered, and optimal control of myeloma is associated with improved outcome. See related video: https://vimeo.com/486246183/559a80cfae See related article by Hultcrantz et al., p. 234.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Myocarditis III: Medical Management
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Myocarditis IV: Nursing Management
Tumor Immunotherapy

